Meeting
2012 ASCO Annual Meeting
A phase I study determining the safety and tolerability of combination therapy with pazopanib, a VEGFR/PDGFR/raf inhibitor, and GSK1120212, a MEK inhibitor, in advanced solid tumors enriched with patients with advanced differentiated thyroid cancer.
Authors
Shabina Roohi Ahmed
The Johns Hopkins University School of Medicine, Baltimore, MD
Shabina Roohi Ahmed , Nilofer Saba Azad , Douglas Wilmot Ball , Michelle A. Rudek , Barry Nelkin , David Cosgrove , Jing Gong , Daniel Finkelstein , Marianna Zahurak , Filip Janku , Melinda Downs , Ashley O'Connor , Susan Markus , Michael Anthony Carducci , Steven I. Sherman , Razelle Kurzrock
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics - Experimental Therapeutics
Track
Developmental Therapeutics
Sub Track
Signal Transduction
Clinical Trial Registration Number
NCT01438554
Citation
J Clin Oncol 30, 2012 (suppl; abstr TPS3117)
DOI
10.1200/jco.2012.30.15_suppl.tps3117
Abstract #
TPS3117
Poster Bd #
22C
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
Phase I, dose-escalation study of the investigational drug TAK-733, an oral MEK inhibitor, in patients (pts) with advanced solid tumors.
First Author: Alex A. Adjei
Poster
2011 ASCO Annual Meeting
First-in-human, multicenter, dose-escalation, phase I study of the investigational drug TAK-733, an oral MEK inhibitor, in patients (pts) with advanced nonhematologic malignancies and melanoma.
First Author: J. A. Sosman
Poster
2023 ASCO Annual Meeting
Phase 1 dose escalation study of DSP107, a first-in-class CD47 and 4-1BB targeting fusion protein, in combination with atezolizumab in patients with advanced solid tumors.
First Author: Anwaar Saeed
Poster
2018 ASCO Annual Meeting
Phase 1 trial of trametinib alone and in combination with dabrafenib in children and adolescents with relapsed solid tumors or neurofibromatosis type 1 (NF1) progressive plexiform neurofibromas (PN).
First Author: Birgit Geoerger